期刊文献+

Phenylacetylglutaminate and Phenylacetate in Combination Upregulate VDUP1, Cause Cell Cycle Blockade and Apoptosis in U87 Glioblastoma Cells

Phenylacetylglutaminate and Phenylacetate in Combination Upregulate VDUP1, Cause Cell Cycle Blockade and Apoptosis in U87 Glioblastoma Cells
下载PDF
导出
摘要 Phenylacetylglutaminate (PG) and Phenylacetate (PN) are metabolites of Phenylbutyrate (PB) and are constituents of antineoplaston AS2-1. These are sodium salts of amino acid derivative and carboxylic acid that inhibit the growth of neoplastic cells without growth inhibitory effect in normal cells. The aim of this study was to identify molecular pathways involved in the anti-proliferative effect of antineoplastons. Using a total human genome microarray we have found that 1) Vitamin D3 upregulated protein (VDUP1) is significantly upregulated in response to PG and PN in the U87 glioblastoma cells;2) Isobologram analysis shows that PG and PN act in an additive or synergistic manner to effectively suppress proliferation of U87 cells;3) PG and PN cause cell cycle arrest, changes in expression of several cell cycle genes and suppress expression and activity of the G2/M checkpoint kinase, CHK1. The multiple cellular targets possibly make these compounds effective anti-proliferative agents. We propose that PG and PN in combination target important cellular pathways and upregulate VDUP1 leading to detachment-induced apoptosis in cancer cells. Phenylacetylglutaminate (PG) and Phenylacetate (PN) are metabolites of Phenylbutyrate (PB) and are constituents of antineoplaston AS2-1. These are sodium salts of amino acid derivative and carboxylic acid that inhibit the growth of neoplastic cells without growth inhibitory effect in normal cells. The aim of this study was to identify molecular pathways involved in the anti-proliferative effect of antineoplastons. Using a total human genome microarray we have found that 1) Vitamin D3 upregulated protein (VDUP1) is significantly upregulated in response to PG and PN in the U87 glioblastoma cells;2) Isobologram analysis shows that PG and PN act in an additive or synergistic manner to effectively suppress proliferation of U87 cells;3) PG and PN cause cell cycle arrest, changes in expression of several cell cycle genes and suppress expression and activity of the G2/M checkpoint kinase, CHK1. The multiple cellular targets possibly make these compounds effective anti-proliferative agents. We propose that PG and PN in combination target important cellular pathways and upregulate VDUP1 leading to detachment-induced apoptosis in cancer cells.
出处 《Journal of Cancer Therapy》 2012年第3期192-200,共9页 癌症治疗(英文)
关键词 GLIOBLASTOMA VDUP1 Phenylacetylglutaminate PHENYLACETATE APOPTOSIS Drug COMBINATION Glioblastoma VDUP1 Phenylacetylglutaminate Phenylacetate Apoptosis Drug Combination
  • 相关文献

参考文献1

二级参考文献24

  • 1Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW,Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997; 57: 4029-35.
  • 2Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2 checkpoint inhibitor. Clin Cancer Res 1996; 2: 791-7.
  • 3Bunch RT, Eastman A. 7-hydroxystaurosporine (UCN-01) causes redistribution of proliferating cell nuclear antigen and abrogates cisplatin-induced S phase arrest in Chinese hamster ovary cells. Cell Growth Differ 1997; 8: 779-88.
  • 4Shao RG, Cao CX, Zhang H, Kohn KW, Wold MS, Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA -dependent protein kinase and dissociates RPA: DNA-PK complexes. EMBO J1999; 18: 1397-406.
  • 5Akinaga S, Gomi K, Morimoto M, Tomaoki T, Okabe M.Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res 1991; 51: 4888-92.
  • 6Seynaeve CM, Kazanietz MG, Blumberg PM, Sausville EA,Worland PJ. Differential inhibition of protein kinase C isozymes by, UCN-01, a staurosporine analogue. Mol Pharmacol 1994; 45: 1207-14.
  • 7Akinaga S, Nomura K, Gomi K, Okabe M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01 a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 1993; 32: 183-9.
  • 8Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, et al. Conservation of the Chkl checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 1997; 277: 1497- 501.
  • 9Rodrigues NR, Rowan A, Smith MEE Kerr IB, Bodmer WF,Gannon JV, et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 1990; 87: 7555-9.
  • 10Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T,Okabe M. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cipl/WAF1/Sdi 1 in p53-mutated human epidermoid carcinoma A431 cells.Cancer Res 19976; 57: 1495-501.

共引文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部